A phase I dose escalation trial of BI 2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC)

Abstract only

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 26; no. 15_suppl; p. 8115
Main Authors Ellis, P. M., Chu, Q. S., Leighl, N. B., Laurie, S. A., Trommeshauser, D., Hanft, G., Munzert, G., Gyorffy, S.
Format Journal Article
LanguageEnglish
Published 20.05.2008
Online AccessGet full text

Cover

More Information
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2008.26.15_suppl.8115